Holen Sie sich die Stockscreener-App
0.958
3.57%
0.033
Handel nachbörslich:
.95
-0.008
-0.84%
Schlusskurs vom Vortag:
$0.925
Offen:
$0.938
24-Stunden-Volumen:
155.20K
Relative Volume:
1.06
Marktkapitalisierung:
$18.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.08M
KGV:
-0.3259
EPS:
-2.94
Netto-Cashflow:
$-25.68M
1W Leistung:
-2.24%
1M Leistung:
-17.15%
6M Leistung:
-51.62%
1J Leistung:
-8.76%
1-Tages-Spanne:
$0.926
$0.9674
1-Wochen-Bereich:
$0.872
$1.01
52-Wochen-Spanne:
$0.872
$2.55
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Firmenname
Chemomab Therapeutics Ltd Adr
Sektor
Branche
Telefon
972-77-331-0156
Adresse
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Vergleichen Sie CMMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
0.958 | 19.73M | 0 | -33.08M | -25.68M | -2.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-13 | Eingeleitet | Maxim Group | Buy |
| 2024-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-12-19 | Fortgesetzt | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Aktie (CMMB) Neueste Nachrichten
CMMB’s Market Whiplash: -34.81% YTD Decline, -15.11% Plunge in 30 Days - investchronicle.com
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy - sharewise
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study - sharewise
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Chemomab prepares for annual shareholder meeting By Investing.com - Investing.com India
Chemomab prepares for annual shareholder meeting - Investing.com
Chemomab Leadership Changes Signal Strategic Momentum Following Positive Clinical Results - Barchart.com
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Microsoft Stock After Xbox Price Hike: Buy Or Hold? - Barchart.com
Should You Buy, Sell, Or Hold Nio Stock Amid Firefly Brand Launch? - Barchart.com
UBS Group Q1 Earnings & Revenues Dip Y/Y, Credit Loss Expenses Slip - Barchart.com
This ‘Strong Buy’ Robotaxi Stock Just Got A Huge Bump. Should You Buy Shares Now? - Barchart.com
Chemomab reports promising PSC treatment data - Investing.com
Chemomab Announces New Medical And Clinical Appointments - Barchart.com
Should You Buy Tesla Stock On The ‘Liberation Day’ Dip? - Barchart.com
Should You Dump Tesla Stock As Deliveries Plunge In Q1 And Tariff Fears Escalate? - Barchart.com
The Aurora Cannabis Inc (NASDAQ: ACB) Stock Price: Is It Overvalued? - Stocks Register
How Stable And Growing Is Globavend Holdings Ltd (NASDAQ: GVH)? - Stocks Register
Before Buying AYRO Inc (NASDAQ: AYRO) Stock, Read This First - Stocks Register
Is Advance Auto Parts Inc (NYSE: AAP) A Good Investment For New Investors Now? - stocksregister.com
Nu Holdings Ltd (NYSE: NU) Has Great Upside Potential - stocksregister.com
ZEEKR Intelligent Technology Holding Ltd. ADR (NYSE: ZK): Getting A Free Pass? - stocksregister.com
AT&T, Inc (NYSE: T) Jumps 1.59%: What Could Be On The Way Going Forward? - Stocks Register
Adma Biologics Inc (NASDAQ: ADMA): Blank Check For Growth? - Stocks Register
A Bullish 2025 Outlook For Blink Charging Co (NASDAQ: BLNK) Shares - Stocks Register
In 2025, Linkers Industries Ltd (NASDAQ: LNKS) Shares Will Likely Be Bullish - Stocks Register
Carrier Global Corp (NYSE: CARR): On Track To A Higher Share Price - Stocks Register
Before Buying Avantor Inc (NYSE: AVTR) Stock, Read This First - stocksregister.com
Ally Financial Inc (NYSE: ALLY): An Enticing Stock To Watch - stocksregister.com
Nebokitug shows promise in PSC treatment trial - Investing.com
Q3 Rundown: Sea (NYSE:SE) Vs Other Online Marketplace Stocks - Barchart.com
Does DLocal Limited (NASDAQ: DLO) Still Need To Convince Analysts? - stocksregister.com
Think You Need A Good Stock? Look At This Scilex Holding Company (NASDAQ: SCLX) Analysis - stocksregister.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - stocksregister.com
Is WeRide Stock A Buy, Sell, Or Hold As Nvidia Reveals Its $25 Million Bet? - Barchart.com
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
How analysts predict Chemomab Therapeutics Ltd ADR (CMMB) will perform this quarter? - US Post News
Nebokitug positioned as potential first FDA-approved PSC treatment By Investing.com - Investing.com South Africa
Arm Just Nabbed A Major Chip Deal With Meta. Is ARM Stock A Buy, Sell, Or Hold Now? - Barchart.com
港股美國預託證券與本港收市比較個別發展 - Yahoo 財經
Nvidia Sends Chinese Self-Driving Stock Up 100%, While Soundhound AI Sells Off - Barchart.com
Up 175% In 2024, Can This Growth Stock Keep Climbing? - Barchart.com
3 Stocks To Benefit From China’s Rare Earth Export Ban On U.S. - Barchart.com
Is Toyota Stock A Buy, Sell, Or Hold On New Return On Equity Plans? - Barchart.com
3 Pharma Stocks To Buy As California Sounds The Alarm On Bird Flu Cases - Barchart.com
What's Going On With Alibaba Stock? - Barchart.com
Finanzdaten der Chemomab Therapeutics Ltd Adr-Aktie (CMMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):